Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates
CompanyDeals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates

Brise Pharmaceuticals Co. Ltd., a portfolio company of Sherpa Healthcare Partners, announced an update on its exclusive license agreement with AbbVie (NYSE: ABBV), originally entered into in 2024. Under the…

CSPC Pharmaceutical Initiates Phase I Clinical Trial of SYS6057 – Self‑Developed Recombinant RSV Vaccine with Dual‑Subtype Preclinical Protection

CSPC Pharmaceutical Initiates Phase I Clinical Trial of SYS6057 – Self‑Developed Recombinant RSV Vaccine with Dual‑Subtype Preclinical Protection

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Innovent Biologics’ GFH925 on Track for Priority Review Status for NSCLC Treatment

CompanyDrug

Zhejiang Jianfeng Receives FDA Approval for JFAN-1001 Clinical Trial in NSCLC

CompanyDrug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Study of Bispecific Antibody NBL-028

CompanyDrug

Shanghai Henlius Initiates Global Phase III Study for HanSiZhuang in LS-SCLC

CompanyDrug

EC Approves AstraZeneca and Daiichi Sankyo’s Enhertu for Advanced HER2+ NSCLC

CompanyDrug

Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023

Company

Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff

CompanyDrug

Fosun Pharma Gains NMPA Approval for Phase I Trial of XS-03 in Advanced Solid Tumors

Show More